Shelby Newsad

Partner at compound-ventures

Reviewed Updated Apr 28, 2026

This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.

Location New York, NY
Check Size $400K-$1.5M
Last Verified Investment Achira (Seed) — Feb 24, 2025
Social @shelbynewsad LinkedIn
Stage Focus
pre-seed seed series-a
Sector Focus
biotech biology healthcare drug-discovery AI computational-biology synthetic-biology autonomous-science cell-therapy digital-health decentralized-science

Background

Shelby Newsad is a Partner at Compound, the New York–based thesis-driven, research-centric investment firm focused on early-stage AI/ML, robotics, biology and healthcare, crypto, and frontier technology 12. Within the Compound team she is the partner most focused on biology and healthcare, and the firm describes her as someone who “has >20 active bio and health theses” and is “dedicated to being a super high context and helpful thought partner” for founders building in those areas 1.

Newsad joined Compound on August 17, 2022, when the firm announced her hire as an Investor focused on Biology and Healthcare; she was later promoted to Partner 34. She holds an undergraduate degree in Biochemistry with an engineering minor from The Ohio State University, an MPhil in Bioscience Enterprise from the University of Cambridge, and a PhD in Plant Sciences from the University of Cambridge (Smith Lab, Plant Sciences Department), where her doctoral research focused on microalgae symbioses 35. Her earlier wet-lab research experience spans neuroscience at the Serpe Lab at the National Institutes of Health in Bethesda, Maryland, and drug discovery at the Titz Lab at the Helmholtz Institute in Saarbrücken, Germany 3.

Before joining Compound, Newsad split her time between bench science and the venture side of life sciences. She interned with Merck KGaA at the company’s Innovation Center in Germany and worked with European VC funds including Hummingbird Ventures, Ahren Innovation Capital, and Start Codon 3. While at Cambridge she ran the university’s Venture Capital and Private Equity Society as chair, building a student program through which more than 70 Cambridge students gained hands-on VC exposure via partnerships with Start Codon, Investiere (Verve Capital Partners), Hummingbird, PwC Ventures, Octopus Ventures, IQ Capital, and Cambridge Innovation Capital 6.

Stated Thesis

Compound publicly describes itself as “a Thesis-Driven, Research-Centric Investment Firm” focused on “Helping accelerate the futures that our founders believe in” across AI/ML, robotics, biology and healthcare, and crypto 2. On Compound’s team page, Newsad is positioned as the partner “committed to facilitating step-change technologies in bio and health” with a self-described portfolio of more than 20 active biology and health investment theses 1.

In her published writing, Newsad has articulated several specific thesis areas. On autonomous science she has written that the firm “dare[s] to call this instantiation a Generation 4 Bio AI” — a stage in which “the discovery and optimization are fully agentic and autonomous in nature” and “where better hypothesis generation and reasoning combine with mega-throughput is where we can start seeing the curve of autonomous science create faster timescales” 7. On post-ZIRP biotech platform companies she has stated that “every company needs to be built to withstand different funding and hype cycles and thus needs dual platform and asset approach” and that founders should “always create a data package sooner rather than later and show from both in vitro, cell, and animal models that your asset is exceptional” 8. On regulatory paths she has argued for the renewed use of human challenge trials, citing that “where Phase IIIs for common inflections such as influenza and COVID-19 cost $100M+, the reported rate for efficacy readouts for HCTs is on the order of mid-seven figures to low-eight figures” 9.

She has also stated Compound’s broader research-centric process explicitly: “Instead of being really numbers-focused and casting a wide net like a lot of VCs do…we intentionally take a step back from the noise and spend probably about half of our time on research” 10.

Inferred Thesis

This analysis is based on 8 verified Compound bio/health investments where Compound’s participation is confirmed by primary or contemporaneous press, plus Compound’s own published portfolio page 11. Compound rarely discloses which partner sourced or led an individual deal; Newsad’s bio/health focus and her firm-published role mean these investments are the strongest available proxy for her individual footprint, but per-deal sourcing attribution is not always public. Treat percentages below as directional rather than statistically definitive.

Sector distribution within the verified bio/health subset (8 investments): AI applied to biology and drug discovery is the dominant theme — Achira (AI + physics for drug discovery), CellVoyant (AI + live cell imaging for stem cell therapies), Pheiron (AI for drug program prioritization using human genetics), and Briefly Bio (AI for protocol reproducibility) account for 4 of 8 (50%). Tissue and cell engineering / regenerative medicine accounts for 2 of 8 (25%) — Polyphron (autonomous tissue foundry, iPSC-derived grafts) and Pear Bio (functional precision oncology with patient tumor microtumors). Reproductive / fertility biology is represented by Conception (in-vitro gametogenesis to make eggs from skin cells) and ImVitro (AI-guided IVF embryo selection) 1112131415161718.

Differentiation from her co-partners at Compound: In Michael Dempsey’s verified portfolio, healthcare/biology accounts for ~23% of confirmed investments and AI/ML for ~46% [Dempsey profile]. In David Hirsch’s Compound-era verified portfolio, healthcare and biology is the single largest verified bucket at ~36% [Hirsch profile]. Newsad’s verified subset over-indexes far more heavily on bio: 100% of her individually-attributable investments confirmed in this profile are biology and healthcare deals. This is consistent with how the Compound team page positions her — as the partner whose deal sourcing is concentrated in bio and health — and with Compound’s published portfolio, where the “Healthcare & Biology” category is the largest single bucket at 22 companies 11.

Stage distribution: Of the 8 verified bio/health investments, the bulk are seed and pre-seed. Briefly Bio was a $1.2M pre-seed 12; Polyphron and Pheiron were seed rounds in the low-to-mid single-digit millions 1314; Pear Bio was a Series A where Compound participated as a follow-on investor 15. Signal by NFX lists Newsad’s check size range as $400K–$1.5M with a $1M sweet spot, consistent with seed-stage initial checks at Compound’s published cadence 4. Signal also lists her active stages as Seed, Series A, and Series B 4.

Geographic focus: Newsad’s verified bio/health portfolio is conspicuously transatlantic. Briefly Bio is London-based 12. CellVoyant is a University of Bristol spinout 16. Pheiron is Berlin-based 14. ImVitro is European 18. Pear Bio is Boston/London 15. Conception is US-based, as is Polyphron 1317. This mix is consistent with VCSheet’s listing of her geography as “USA, Europe” rather than US-only 19 and with her own UK academic and venture roots (Cambridge PhD; prior work with Hummingbird Ventures and Start Codon) 3.

Founder profile patterns: The verified bio/health investments share an unusually consistent founder profile: deeply technical and often academia-spinout. CellVoyant CEO Rafael Carazo Salas is a University of Bristol professor 16. Briefly Bio was founded by Dr. Katya Putintseva, Harry Rickerby, and Staffan Piledahl, with backgrounds in computational biology, software, and bioscience 12. Achira’s Theofanis Karaletsos has stated the company aims to make drug discovery “90% compute and 10% experiment” — a statement compatible with Newsad’s published thesis that “for small molecules interacting with confined protein regions, the data isn’t as necessary in the next three to five years” 2010.

Co-investor patterns: Across her verified bio/health portfolio, Compound has repeatedly co-invested with: Hummingbird Ventures (Pheiron — also Newsad’s prior employer) 14; Octopus Ventures (Pear Bio Series A; CellVoyant seed) 1516; Fly Ventures (Pear Bio, ImVitro) 1518; Tiny VC (ImVitro, Briefly Bio) 1812; OpenAI (Red Queen Bio seed) 21; Dimension, Amplify Partners, and NVentures/NVIDIA (Achira seed) 20; Humba Ventures, R7, and Vento (Polyphron seed) 13. Signal by NFX additionally lists frequent network co-investors including Charles Hudson (Precursor Ventures), Gokul Rajaram, and Leo Polovets (Humba Ventures) 4.

Notable patterns vs. stated thesis: Newsad’s published thesis emphasizes autonomous science, AI in bio, cell therapies, decentralized science, and human challenge trials. The verified portfolio matches the autonomous-science and AI-in-bio framing closely (Achira, CellVoyant, Pheiron, Briefly Bio, Polyphron) but contains less direct evidence so far for her decentralized-science and biosecurity theses, despite her Substack output emphasizing both. Red Queen Bio (AI biosecurity, OpenAI-led seed in 2025 21) is the clearest biosecurity confirmation. Decentralized-science investments at Compound have historically been crypto-team led (Compound’s separate Compound Crypto practice) rather than Newsad-led.

Notable gap: Compound’s published portfolio lists 22 companies in Healthcare & Biology 11; this profile verifies only 8 of those with primary or contemporaneous round-level citations. Several Compound bio companies (Atlas, Boost Biomes, Chemical Synthesis Co., Culture Biosciences, Juvena Therapeutics, Los Angeles Project, Minibinders Co., Spaero Bio, SuppCo, Vitae) appear on Compound’s site but lacked the public funding announcements needed to attribute a specific Compound check to a specific round in the time budget for this profile.

Portfolio

Company Year Stage Source
ImVitro 2022-12 Seed 18
Pear Bio 2023-05 Series A (follow-on) 15
Pheiron ~2023 Seed 14
~unknown Conception (multiple rounds) Seed/follow-on
CellVoyant 2024-01 Seed 1116
Polyphron 2024 Seed 13
Briefly Bio 2024-07-17 Pre-seed (Compound-led) 12
Achira 2025-02-24 Seed 20
Red Queen Bio 2025-12 Seed 21

This table represents 9 of an unknown larger set — Compound’s published portfolio lists 22 companies in its Healthcare & Biology bucket alone 11, and Newsad has stated she runs “20+ active theses” 1. The entries above are the rounds in Compound’s bio/health portfolio with confirmed primary or contemporaneous press citations. Per-deal lead-partner attribution at Compound is rarely public; the table reflects firm-level Compound participation in bio/health rounds rather than Newsad’s individual deal sourcing in most cases. Briefly Bio is the strongest individually-attributable example because Newsad provided the on-record investor quote in the launch announcement 12.

In Their Own Words

“Whereas most bio software companies focus on data and its analysis, Briefly goes upstream to the core problem space of reproducibility via protocols.” — Shelby Newsad, on the Briefly Bio pre-seed announcement, July 17, 2024 12

“Instead of being really numbers-focused and casting a wide net like a lot of VCs do…we intentionally take a step back from the noise and spend probably about half of our time on research.” — Shelby Newsad, Republic of Science / ML4Sci interview 10

“I think a lot of the AI field is actually further advanced than what people in big industries…realize. I think a lot of people would benefit if they spent maybe one to two hours a week just reading AI papers.” — Shelby Newsad, Republic of Science / ML4Sci interview 10

“The consensus answer is that you will need data for a long time. The non-consensus answer is that for small molecules interacting with confined protein regions, the data isn’t as necessary in the next three to five years.” — Shelby Newsad, on in-silico vs. experimental data, Republic of Science / ML4Sci interview 10

“We really wish more people were working in biosecurity. With measles outbreaks, avian flu in people without bird exposure…it’s clearly a longevity and national security issue.” — Shelby Newsad, on underinvested areas, Republic of Science / ML4Sci interview 10

“Companies who raised in ZIRP on the pretense of building the ‘best’ platform, they’ve by and large struggled… every company needs to be built to withstand different funding and hype cycles and thus needs dual platform and asset approach.” — Shelby Newsad, “Building Bio Platforms in 2024,” Biocene Thoughts Substack 8

“We dare to call this instantiation a Generation 4 Bio AI… the discovery and optimization are fully agentic and autonomous in nature.” — Shelby Newsad, “Commercializing Autonomous Science,” Biocene Thoughts Substack, February 6, 2025 7

“It’s materially easier to raise $5M vs. $100M. This especially is valuable if you’re a first time founder.” — Shelby Newsad, on why human challenge trials shorten capital needs, “Scaling Human Challenge Trials,” Biocene Thoughts Substack, March 17, 2026 9

“Cell therapies currently exist in an instant of deceptive potential — obscured by a short-term trough of disillusionment.” — Shelby Newsad, “Cell Therapies, Living Medicines,” Biocene Thoughts Substack, February 27, 2025 22

What Founders Say

No independently sourced founder testimonials found. Newsad is repeatedly described as a “high-context thought partner” by Compound’s own team page 1, and Compound’s portfolio includes multiple bio companies whose founders have publicly thanked the firm in announcements (Briefly Bio, Achira, Pear Bio, CellVoyant, Pheiron). However, first-person founder quotes specifically describing what it is like to work with Newsad as an investor were not located in the time budget for this profile. Standard searches surfaced press releases that name Compound at the firm level but rarely attribute a Compound partner to a specific deal beyond Newsad’s own on-record quote in Briefly Bio’s launch 12.

Connections

  • Compound team partner — works with Managing Partner Michael Dempsey, General Partner David Hirsch, Partner 0xSmac, and venture partners including Drew Gray (AI/Robotics), John Palmer (Crypto), Ron Boger (Computational Biology), Celeste Holz-Schietinger (Biology), and Dan Zigmond (Data Science & AI) 12
  • Prior employer: Hummingbird Ventures — worked with the European VC during her Cambridge years; Hummingbird later co-invested with Compound on Pheiron’s seed round 314
  • Prior employer: Ahren Innovation Capital — UK deep-tech / life sciences fund 3
  • Prior employer: Start Codon — Cambridge, UK biotech accelerator and seed fund 3
  • Prior employer: Merck KGaA Innovation Center (Germany) — internship in corporate innovation 3
  • Cambridge VCPE Society — chair of the University of Cambridge Venture Capital and Private Equity Society; built a student-run program with 70+ student participants and partnerships with Start Codon, Investiere/Verve, Hummingbird, PwC Ventures, Octopus Ventures, IQ Capital, and Cambridge Innovation Capital 6
  • Doctoral training — PhD in Plant Sciences, University of Cambridge (Smith Lab); MPhil in Bioscience Enterprise, University of Cambridge 3
  • Frequent bio co-investors — Octopus Ventures (Pear Bio, CellVoyant), Hummingbird Ventures (Pheiron), Fly Ventures (Pear Bio, ImVitro), Tiny VC (ImVitro, Briefly Bio), Dimension and Amplify Partners and NVentures (Achira), OpenAI and Halcyon Futures (Red Queen Bio) 14151618122021

Sources

  1. Compound, “Shelby Newsad” team page, accessed April 2026. https://www.compound.vc/team/shelbyn↩↩↩↩↩↩

  2. Compound, “About us” page, accessed April 2026. https://www.compound.vc/about↩↩↩

  3. Compound (Medium), “Welcome Shelby. Shelby Newsad has joined the investment…”, August 17, 2022. https://compoundvc.medium.com/welcome-shelby-7ec82348de35↩↩↩↩↩↩↩↩↩↩

  4. Signal by NFX, “Shelby Newsad’s Investing Profile — Compound Investor,” accessed April 2026. https://signal.nfx.com/investors/shelby-newsad↩↩↩↩

  5. Shelby Newsad on LinkedIn, accessed April 2026. https://www.linkedin.com/in/shelbynewsad/↩

  6. Verve Ventures interview, “The next generation of venture capitalists” (with Shelby Newsad and Michelle Parker), accessed April 2026. https://www.verve.vc/blog/interview-cambridge-shelby-newsad-michelle-parker/↩↩

  7. Shelby Newsad (Biocene Thoughts Substack), “Commercializing Autonomous Science,” February 6, 2025. https://shelbyann.substack.com/p/commercializing-autonomous-science↩↩

  8. Shelby Newsad (Biocene Thoughts Substack), “Building Bio Platforms in 2024,” March 5, 2024. https://shelbyann.substack.com/p/building-bio-platforms-in-2024↩↩

  9. Shelby Newsad (Biocene Thoughts Substack), “Scaling Human Challenge Trials,” March 17, 2026. https://shelbyann.substack.com/p/scaling-human-challenge-trials↩↩

  10. Republic of Science / ML4Sci, “Shelby Newsad on the Venture Thesis for Autonomous Science,” accessed April 2026. https://republicofscience.substack.com/p/shelby-newsad-on-the-venture-thesis↩↩↩↩↩↩

  11. Compound, “Portfolio,” accessed April 2026. https://www.compound.vc/portfolio↩↩↩↩↩↩

  12. TechFundingNews, “Briefly Bio raises $1.2M pre-seed to revolutionise scientific experiment documentation with AI,” July 17, 2024. https://techfundingnews.com/briefly-bio-lab-experiment-reproducibility/↩↩↩↩↩↩↩↩↩↩

  13. Polyphron F4 Fund profile (round details and Compound participation), accessed April 2026. https://f4.fund/startups/polyphron↩↩↩↩↩

  14. CB Insights, “Pheiron — Products, Competitors, Financials,” accessed April 2026. https://www.cbinsights.com/company/pheiron↩↩↩↩↩↩↩

  15. Sifted, “This startup can predict the success of complex cancer treatments” (Pear Bio $14M Series A), May 15, 2023. https://sifted.eu/articles/pear-bio-raise-series-a-news↩↩↩↩↩↩↩

  16. University of Bristol News, “CellVoyant secures £7.6m seed funding,” January 18, 2024. https://www.bristol.ac.uk/news/2024/january/cellvoyant-funding.html↩↩↩↩↩↩

  17. Conception F4 Fund profile (Compound listed as investor), accessed April 2026. https://f4.fund/startups/conception-bio↩↩

  18. FemtechInsider, “ImVitro Raises $2.5M in Seed Funding to Increase IVF Clinic Workflow Efficiency and Maximize Success with AI,” December 2022. https://femtechinsider.com/imvitro-seed-round/↩↩↩↩↩↩

  19. VCSheet, “Shelby Newsad (Compound) — VC Breakdown & Contact,” accessed April 2026. https://www.vcsheet.com/who/shelby-newsad↩

  20. The Recursive, “Greek co-founded Achira secures €31.54M with NVIDIA’s backing,” February 24, 2025. https://therecursive.com/greek-co-founded-achira-secures-e31-54m-with-nvidia-s-backing/↩↩↩↩

  21. TechInformed, “OpenAI leads $15 million seed in Red Queen Bio for AI biosecurity,” December 2025. https://techinformed.com/openai-leads-15-million-seed-in-red-queen-bio-for-ai-biosecurity/↩↩↩↩

  22. Shelby Newsad (Biocene Thoughts Substack), “Cell Therapies, Living Medicines,” February 27, 2025. https://shelbyann.substack.com/p/cell-therapies-living-medicines↩